June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Efficacy and safety of ranibizumab in diabetic macular edema: real life study
Author Affiliations & Notes
  • Linda Hrarat
    AVICENNE, PARIS, France
  • Franck Fajnkuchen
    AVICENNE, PARIS, France
  • valerie sarda
    AVICENNE, PARIS, France
  • marouane boubaya
    AVICENNE, PARIS, France
  • thyphaine grenet
    AVICENNE, PARIS, France
  • chaine gilles
    AVICENNE, PARIS, France
  • Audrey Giocanti
    AVICENNE, PARIS, France
  • Footnotes
    Commercial Relationships   Linda Hrarat, None; Franck Fajnkuchen, None; valerie sarda, None; marouane boubaya, None; thyphaine grenet, None; chaine gilles, None; Audrey Giocanti, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1890. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Linda Hrarat, Franck Fajnkuchen, valerie sarda, marouane boubaya, thyphaine grenet, chaine gilles, Audrey Giocanti; Efficacy and safety of ranibizumab in diabetic macular edema: real life study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1890.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the efficacy and safety of ranibizumab in patients with vision loss secondary to diabetic macular edema (DME).

Methods : Retrospective analysis of consecutive patients with vision loss due to DME and treated with ranibizumab. All patients received a loading dose of 3 monthly injections followed by re-treatments on an as needed basis. Primary endpoint was the change in best-corrected visual acuity (BCVA) at 12 months. Secondary endpoints were the change in central retinal thickness (CRT) and number of intravitreal injections (IVI) at 12 months.

Results : One hundred and six eyes of 78 patients were included. BCVA changed from 48.3 letters at baseline to 59 letters at 12 months (p <0.0001) (mean gain: +10.7 letters) and 38% of patients had a final BCVA >70 letters. CRT decreased from 519 μm at baseline to 355 μm at 12 months (p <0.0001). The threshold of the first quartile of the baseline VA was 40 letters. Patients with a baseline VA >40 letters had a higher final VA of 66 ± 14 letters vs 43 ± 18 letters for patients with a baseline VA ≤40 letters (p <0.0001). A mean number of 5.4 (3-10) IVI were administered.

Conclusions : This study conducted in a clinical setting confirms the results of previous randomized trials. The final BCVA was mainly impacted by the baseline BCVA, which supports the early treatment of DME before patients experience a severe vision loss.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×